LexaGene Holdings Inc a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into a collaborative agreement with Texas A&M Veterinary Medical Diagnostics Laboratory.
Under this agreement , Texas A&M will provide canine urine samples to LexaGene for testing on the Company’s LX6 prototype for more effective pathogen detection. Prior to sending the samples to LexaGene, Texas A&M will characterize them using conventional diagnostic technologies.“
We are happy to add Texas A&M to our growing list of collaborators that are sending us samples , as this allows us to continue to refine our assays and optimize the LX6 prototype. It is important for us to work with collaborators in different geographic regions to get adequate representation of diseases that thrive in different climates,” said Dr. Jack Regan, LexaGene’s CEO.
He continues, “For example, Rickettsia (Rocky Mountain spotted fever) is a tick-borne infection that commonly affects dogs in the Mid-West and Southern states, but is found less often in the Northern states. Conversely, Borrelia burgdorferi and Anaplasma phagocytophilum are common dog pathogens in the Northeast, but are rarely found in the South.
For this reason, we need to have collaborators in all corners of the United States to ensure the LX6 is equally effective in each state .”
